Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥20 and ≤60 years of age~* In good health as determined by medical history, physical examination, and clinical judgment of the investigator~* Willing and able to comply with all required study visits and follow-up required by this protocol~* Must provide written informed consent~Exclusion Criteria:~* Known or potential exposure to avian influenza virus or any H5N1 HA antigen vaccine~* Had any influenza vaccine within 6 months~* Administered with any vaccine within 30 days~* A history of hypersensitivity to vaccines or inflammatory or degenerative neurological disease~* Receiving chronic administration of immunosuppressants or other immune-modifying drugs within 6 months~* Known HIV, hepatitis B (HBsAg) or hepatitis C seropositivity~* Any medical illness including clinically significant acute pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests~* Receiving immunoglobulins and/or any blood products within the three months~* Acute disease at the time of enrolment~* Psychiatric, addictive, or any disorder, which may compromise the ability to give a truly informed consent for participation of this study or adequate compliance~* Breast feeding or pregnant women

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Low Dosage AT-301 (Type: EXPERIMENTAL): 7.5 µg hemagglutinin (HA)
- Middle Dosage AT-301 (Type: EXPERIMENTAL): 15 µg hemagglutinin (HA)
- High Dosage AT-301 (Type: EXPERIMENTAL): 30 µg hemagglutinin (HA)

Based on this trial design, predict the completion outcome and termination type (if applicable).